Is L-Carnitine Supplementation Beneficial in 3-Methylcrotonyl-CoA Carboxylase Deficiency?

Overview

Journal JIMD Rep

Publisher Wiley

Date 2015 Mar 4

PMID 25732994

Citations 7

Authors

Jakup Andreas Thomsen

Allan Meldgaard Lund

Jess Have Olesen

Magni Mohr

Jan Rasmussen

Affiliations

Soon will be listed here.

Abstract

Background: 3-Methylcrotonyl-CoA carboxylase deficiency (3-MCCd) is an autosomal recessive disorder in the catabolism of leucine. In the present study, we investigated the current and prior medical condition of patients with 3-MCCd in the Faroe Islands and their carnitine levels in blood, urine and muscle tissue with and without L-carnitine supplementation to evaluate the current treatment strategy of not recommending L-carnitine supplementation to Faroese 3-MCCd patients.

Methods: Blood and urine samples and muscle biopsies were collected from patients at inclusion and at 3 months. Eight patients received L-carnitine supplementation when recruited; five did not. Included patients who received supplementation were asked to stop L-carnitine, the others were asked to initiate L-carnitine supplementation during the study. Symptoms were determined by review of hospital medical records and questionnaires answered at baseline and after the intervention.

Results: The prevalence of 3-MCCd in the Faroe Islands was 1:2,400, the highest reported worldwide. All patients were homozygous for the MCCC1 mutation c.1526delG. When not administered L-carnitine, the 3-MCCd patients (n = 13) had low plasma and muscle free carnitine levels, 6.9 (SD 1.4) μmol/L and 785 (SD 301) nmol/g wet weight, respectively. L-Carnitine supplementation increased muscle and plasma carnitine levels to a low-normal range, 25.5 (SD 10.9) μmol/L and 1,827 (SD 523) nmol/g wet weight, p < 0.01, respectively. Seven of the thirteen 3-MCCd subjects suffered from self-reported fatigue with some alleviation after L-carnitine supplementation.

Conclusion: 3-MCCd is common in the Faroe Islands. Some symptomatic 3-MCCd patients may benefit biochemically and clinically from L-carnitine supplementation, a more general recommendation cannot be given.

Citing Articles

Newborn screening and genetic diagnosis of 3-methylcrotonyl-CoA carboxylase deficiency in Quanzhou,China.

Lin W, Wang K, Chen Y, Zheng Z, Lin Y Mol Genet Metab Rep. 2024; 40:101127.

PMID: 39188588 PMC: 11345313. DOI: 10.1016/j.ymgmr.2024.101127.

Exploring the molecular and clinical spectrum of COVID-19-related acute necrotizing encephalopathy in three pediatric cases.

Wu D, Zheng Y, Li Y, Peng M, Lin H, Wang K J Hum Genet. 2023; 68(11):769-775.

PMID: 37491516 DOI: 10.1038/s10038-023-01171-z.

A Unique Presentation of 3-Methylcrotonyl-CoA Carboxylase Deficiency.

Jagadish A, Sclater K, Lapinski T, Adkins K, Selzer L Cureus. 2023; 15(5):e39401.

PMID: 37362523 PMC: 10287026. DOI: 10.7759/cureus.39401.

FarGen: Elucidating the distribution of coding variants in the isolated population of the Faroe Islands.

Mortensen O, Thomsen E, Lydersen L, Apol K, Weihe P, Steig B Eur J Hum Genet. 2022; 31(3):329-337.

PMID: 36404349 PMC: 9995356. DOI: 10.1038/s41431-022-01227-2.

Biochemical and molecular characterization of 3-Methylcrotonylglycinuria in an Italian asymptomatic girl.

Cozzolino C, Villani G, Frisso G, Scolamiero E, Albano L, Gallo G Genet Mol Biol. 2018; 41(2):379-385.

PMID: 29767664 PMC: 6082241. DOI: 10.1590/1678-4685-GMB-2017-0093.

References

Baumgartner M, Almashanu S, Suormala T, Obie C, Cole R, Packman S . The molecular basis of human 3-methylcrotonyl-CoA carboxylase deficiency. J Clin Invest. 2001; 107(4):495-504. PMC: 199271. DOI: 10.1172/JCI11948. View

Gallardo M, Desviat L, Rodriguez J, Esparza-Gordillo J, Perez-Cerda C, Perez B . The molecular basis of 3-methylcrotonylglycinuria, a disorder of leucine catabolism. Am J Hum Genet. 2001; 68(2):334-46. PMC: 1235267. DOI: 10.1086/318202. View

Wilcken B, Wiley V, Hammond J, Carpenter K . Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med. 2003; 348(23):2304-12. DOI: 10.1056/NEJMoa025225. View

Koeberl D, Millington D, Smith W, Weavil S, Muenzer J, McCandless S . Evaluation of 3-methylcrotonyl-CoA carboxylase deficiency detected by tandem mass spectrometry newborn screening. J Inherit Metab Dis. 2003; 26(1):25-35. DOI: 10.1023/a:1024015227863. View

Opalka J, Gellerich F, Zierz S . Age and sex dependency of carnitine concentration in human serum and skeletal muscle. Clin Chem. 2001; 47(12):2150-3. View

Rasmussen J, Nielsen O, Lund A, Kober L, Djurhuus H . Primary carnitine deficiency and pivalic acid exposure causing encephalopathy and fatal cardiac events. J Inherit Metab Dis. 2012; 36(1):35-41. DOI: 10.1007/s10545-012-9488-8. View

Baykal T, Gokcay G, Ince Z, Dantas M, Fowler B, Baumgartner M . Consanguineous 3-methylcrotonyl-CoA carboxylase deficiency: early-onset necrotizing encephalopathy with lethal outcome. J Inherit Metab Dis. 2005; 28(2):229-33. DOI: 10.1007/s10545-005-4559-8. View

Bergstrom J . Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest. 1975; 35(7):609-16. View

Schulze A, Lindner M, Kohlmuller D, Olgemoller K, Mayatepek E, Hoffmann G . Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics. 2003; 111(6 Pt 1):1399-406. DOI: 10.1542/peds.111.6.1399. View

10.

Rasmussen J, Nielsen O, Janzen N, Duno M, Gislason H, Kober L . Carnitine levels in 26,462 individuals from the nationwide screening program for primary carnitine deficiency in the Faroe Islands. J Inherit Metab Dis. 2013; 37(2):215-22. DOI: 10.1007/s10545-013-9606-2. View

11.

Lam C, Carter J, Cederbaum S, Neidich J, Gallant N, Lorey F . Analysis of cases of 3-methylcrotonyl CoA carboxylase deficiency (3-MCCD) in the California newborn screening program reported in the state database. Mol Genet Metab. 2013; 110(4):477-83. DOI: 10.1016/j.ymgme.2013.09.006. View

12.

Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P . Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of.... J Am Soc Echocardiogr. 2005; 18(12):1440-63. DOI: 10.1016/j.echo.2005.10.005. View

13.

Roschinger W, Millington D, Gage D, Huang Z, Iwamoto T, Yano S . 3-Hydroxyisovalerylcarnitine in patients with deficiency of 3-methylcrotonyl CoA carboxylase. Clin Chim Acta. 1995; 240(1):35-51. DOI: 10.1016/0009-8981(95)06126-2. View

14.

Jorgensen T, Degn B, Wang A, Vang M, Gurling H, Kalsi G . Linkage disequilibrium and demographic history of the isolated population of the Faroe Islands. Eur J Hum Genet. 2002; 10(6):381-7. DOI: 10.1038/sj.ejhg.5200816. View

15.

Holzinger A, Roschinger W, Lagler F, Mayerhofer P, Lichtner P, Kattenfeld T . Cloning of the human MCCA and MCCB genes and mutations therein reveal the molecular cause of 3-methylcrotonyl-CoA: carboxylase deficiency. Hum Mol Genet. 2001; 10(12):1299-306. DOI: 10.1093/hmg/10.12.1299. View

16.

Arnold G, Koeberl D, Matern D, Barshop B, Braverman N, Burton B . A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiency. Mol Genet Metab. 2007; 93(4):363-70. DOI: 10.1016/j.ymgme.2007.11.002. View

17.

Madsen K, Preisler N, Orngreen M, Andersen S, Olesen J, Lund A . Patients with medium-chain acyl-coenzyme a dehydrogenase deficiency have impaired oxidation of fat during exercise but no effect of L-carnitine supplementation. J Clin Endocrinol Metab. 2013; 98(4):1667-75. DOI: 10.1210/jc.2012-3791. View

18.

Baumgartner M, Dantas M, Suormala T, Almashanu S, Giunta C, Friebel D . Isolated 3-methylcrotonyl-CoA carboxylase deficiency: evidence for an allele-specific dominant negative effect and responsiveness to biotin therapy. Am J Hum Genet. 2004; 75(5):790-800. PMC: 1182108. DOI: 10.1086/425181. View

19.

Dirik E, Yis U, Pasaoglu G, Chambaz C, Baumgartner M . Recurrent attacks of status epilepticus as predominant symptom in 3-methylcrotonyl-CoA carboxylase deficiency. Brain Dev. 2007; 30(3):218-20. DOI: 10.1016/j.braindev.2007.08.005. View

20.

Eminoglu F, Ozcelik A, Okur I, Tumer L, Biberoglu G, Demir E . 3-Methylcrotonyl-CoA carboxylase deficiency: phenotypic variability in a family. J Child Neurol. 2009; 24(4):478-81. DOI: 10.1177/0883073808324536. View